Dieta frugívora dos gêneros de morcegos Artibeus, Carollia e Sturnira (Phyllostomidae, Chiroptera) ao longo de sua distribuição geográfica.

Editores técnicos: Marcílio José Thomazini, Elenice Fritzsons, Patrícia Raquel Silva, Guilherme Schnell e Schuhli, Denise Jeton Cardoso, Luziane Franciscon. EVINCI. Resumos

Consistency in fruit preferences across the geographical range of the frugivorous bats Artibeus, Carollia and Sturnira (Chiroptera).

Os filostomídeos frugívoros Artibeus, Carollia e Sturnira são importantes dispersores de sementes na região Neotropical, se destacando por possuírem uma suposta preferência por frutos dos gêneros Ficus, Piper e Solanum, respectivamente. Nós realizamos uma metanálise para testar a hipótese de que as interações entre esses morcegos e plantas são consistentes ao longo de toda sua distribuição geográfi ca. Por meio de uma extensa revisão bibliográfi ca, foram compilados 4.448 registros de consumo de frutos provenientes de 180 publicações. Estes dados foram organizados por espécie de morcego e país, testando quais gêneros de frutos foram mais frequentes na região neotropical como um todo e em cada um dos seus países componentes. Num panorama geral, os resultados demonstraram alta frequência no consumo de Ficus (24,0%) por Artibeus, Piper (38,7%) por Carollia e Solanum (31,0%) por Sturnira, considerando 176 gêneros botânicos citados. O estudo corrobora, assim, a hipótese da consistência da dieta desses morcegos ao longo de toda a sua distribuição geográfi ca, sendo esta relacionada à ampla distribuição dos grupos (morcegos e plantas) envolvidos, à fenologia das espécies zoocóricas consumidas e à fi delidade espacial dos morcegos, esta, por sua vez, moldada pela capacidade de voo das diferentes espécies

Testes com óleos essenciais e morcegos frugívoros em cativeiro.

Resumo

Diversity of vaginal microbiome and metabolome during genital infections

We characterized the vaginal ecosystem during common infections of the female genital tract, as vulvovaginal candidiasis (VVC, n\u2009=\u200918) and Chlamydia trachomatis infection (CT, n\u2009=\u200920), recruiting healthy (HC, n\u2009=\u200921) and bacterial vaginosis-affected (BV, n\u2009=\u200920) women as references of eubiosis and dysbiosis. The profiles of the vaginal microbiome and metabolome were studied in 79 reproductive-aged women, by means of next generation sequencing and proton based-nuclear magnetic resonance spectroscopy. Lactobacillus genus was profoundly depleted in all the genital infections herein considered, and species-level analysis revealed that healthy vaginal microbiome was dominated by L. crispatus. In the shift from HC to CT, VVC, and BV, L. crispatus was progressively replaced by L. iners. CT infection and VVC, as well as BV condition, were mainly characterised by anaerobe genera, e.g. Gardnerella, Prevotella, Megasphaera, Roseburia and Atopobium. The changes in the bacterial communities occurring during the genital infections resulted in significant alterations in the vaginal metabolites composition, being the decrease of lactate a common marker of all the pathological conditions. In conclusion, according to the taxonomic and metabolomics analysis, we found that each of the four conditions is characterized by a peculiar vaginal microbiome/metabolome fingerprint

EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Background: Limited data are available regarding the use of nab-paclitaxel in older patients with breast cancer. A weekly schedule is recommended, but there is a paucity of evidence regarding the optimal dose. We evaluated the efficacy of two different doses of weekly nab-paclitaxel, with a specific focus on their corresponding impact on patient function, in order to address the lack of data specifically relating to the older population. Methods: EFFECT is an open-label, phase II trial wherein 160 women with advanced breast cancer aged 65 65 years were enrolled from 15 institutions within Italy. Patients were randomly assigned 1:1 to receive nab-paclitaxel 100 mg/m2 (arm A) or 125 mg/m2 (arm B) on days 1, 8, and 15 on a 28-day cycle, as first-line treatment for advanced disease. The primary endpoint was event-free survival (EFS), wherein an event was defined as disease progression (PD), functional decline (FD), or death. In each arm, the null hypothesis that the median EFS would be 64 7 months was tested against a one-sided alternative according to the Brookmeyer Crowley test. Secondary endpoints included objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. Results: After a median follow-up of 32.6 months, 140 events were observed in 158 evaluable patients. Median EFS was 8.2 months (90% CI, 5.9-8.9; p = 0.188) in arm A vs 8.3 months (90% CI, 6.2-9.7, p = 0.078) in arm B. Progression-free survival, overall survival, and response rates were similar in both groups. A higher percentage of dose reductions and discontinuations due to adverse events (AEs) was noted in arm B. The most frequently reported non-haematological AEs were fatigue (grade [G] 2-3 toxicity occurrence in arm A vs B, 43% and 51%, respectively) and peripheral neuropathy (G2-3 arm A vs B, 19% and 38%, respectively). Conclusion: Pre-specified outcomes were similar in both treatment arms. However, 100 mg/m2 was significantly better tolerated with fewer neurotoxicity-related events, representing a more feasible dose to be recommended for older patients with advanced disease. Trial registration: EudraCT, 2012-002707-18. Registered on June 4, 2012. NIH ClinicalTrials.gov, NCT02783222. Retrospectively registered on May 26, 2016